A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.

Trial Details

NCT ID
NCT07735546
Phase
PHASE1
Sponsor
Umoja Biopharma
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • UB-VV500
  • Rapamycin (sirolimus)
Locations (sample)
  • Westmead, New South Wales, Australia|-33.80383,150.98768

Key Eligibility Criteria

  • 18 years or older
  • Provides voluntary written informed consent
  • Relapsed or refractory multiple myeloma (MM) following treatment with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody
  • Measurable disease following completion of most recent anticancer therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →